Drug stocks, fortified by hopes of bigger US sales, lifted European shares on Friday to end the week flat, though still near their best levels of the year.
The FTSE Eurotop 300 index ended the day up 0.5 percent at 939.91 points, with more than two shares rising for each one falling.
The benchmark struggled to match this year's peak set last week as Wall Street trading was mixed, but is up 10.5 percent for the year after its hefty rally from a six-year nadir in March.
"The market is no longer as good value as it was. Although we have a lot of headwind behind it with economic data coming up nicely, we have had several months in a row of good performance and I would not be surprised to see a pause," said Richard Champion of Pavilion Asset Management.
Among the standouts, ING Groep fell 1.4 percent to 18.6 euros as the Dutch firm, Europe's number three insurer, offered cautious guidance after reporting a weaker than expected third-quarter net operating profit.
Italian bank Capitalia reported forecast-beating quarterly numbers, sending its shares higher.
Parmalat ended the week down 12 percent on concerns about the Italian food group's balance sheet, sinking further on Friday on news its finance director had resigned.
Autos lagged as new car sales in western Europe slipped last month, and a dip in US retail sales last month was blamed on weaker demand. Europe's biggest carmaker Volkswagen said it would cut investment over the next five years, and its stock eased a touch to 44.9 euros.
The DJ Euro Stoxx 50 index, a benchmark of euro zone blue chips, closed up 0.8 percent at 2,656.9 points, while the FTSE 100 in London clocked up its best close since late August last year after hitting fresh yearly highs.
The construction sector benefited from signs of a European and Japanese economic recovery, hitting new highs for the year.
Glass maker Saint-Gobain rose three percent, while cement makers Lafarge, Holcim and Heidelbergercement all rose two percent or more.
"We are having a bit more rotation into what has underperformed, like some of the cyclicals. People are scouting around for what has not been involved in the rally," Champion said.
The DJ Stoxx health index hit yearly high on hopes reform of the US Medicare program for seniors would boost demand for prescription medicines in the world's biggest market.
"Investors are getting more confident that there will be a Medicare drug benefit passed in the near term," said Marc Booty, pharmaceuticals analyst at Commerzbank.
Pavilion Asset Management's Champion said it was too early to call a turn in the healthcare sector.
French drug firm Aventis SA rose 5.8 percent, while Britain's GlaxoSmithKline Plc tacked on 2.4 percent. Swiss Novartis AG rallied 3.7 percent, while Anglo-Swedish AstraZeneca gained 2.8 percent.
The Eurotop 300 index is only some six points from its yearly high set a week ago, underpinned by third-quarter earnings, the best since the start of 2000, and further signs of recovery.
Eurostat data on Friday confirmed the euro zone economy grew at 0.4 percent in the third quarter, its fastest rate in a year, and should pick up even more steam in the next six months.
Data on Friday showed a strong improvement in the University of Michigan index of US consumer confidence, and a surprise rise in producer prices.
After investors pushed stocks to new highs, there remained nagging doubts about the rally's sustainability, said Anais Faraj, strategist at Nomura.
"We remain positive, though acknowledge the rough terrain," Faraj added.
JP Morgan investment bank said global growth was supporting European equities and, at this point in the economic cycle, equities usually outperform bonds as earnings grow while bond yields see little lift, thus reducing pressure on a stock's valuation multiple.
In New York, as bourses shut the Dow Jones Industrial Average was flat at 9,846 points, while the NASDAQ Composite had shed 0.6 percent to 1,956 points.
Taiwan’s foreign exchange reserves fell below the US$600 billion mark at the end of last month, with the central bank reporting a total of US$596.89 billion — a decline of US$8.6 billion from February — ending a three-month streak of increases. The central bank attributed the drop to a combination of factors such as outflows by foreign institutional investors, currency fluctuations and its own market interventions. “The large-scale outflows disrupted the balance of supply and demand in the foreign exchange market, prompting the central bank to intervene repeatedly by selling US dollars to stabilize the local currency,” Department of Foreign
ENERGY ISSUES: The TSIA urged the government to increase natural gas and helium reserves to reduce the impact of the Middle East war on semiconductor supply stability Chip testing and packaging service provider ASE Technology Holding Co (日月光投控) yesterday said it planned to invest more than NT$100 billion (US$3.15 billion) in building a new advanced chip testing facility in Kaohsiung to keep up with customer demand driven by the artificial intelligence (AI) boom. That would be included in the company’s capital expenditure budget next year, ASE said. There is also room to raise this year’s capital spending budget from a record-high US$7 billion estimated three months ago, it added. ASE would have six factories under construction this year, another record-breaking number, ASE chief operating officer Tien Wu
The EU and US are nearing an agreement to coordinate on producing and securing critical minerals, part of a push to break reliance on Chinese supplies. The potential deal would create incentives, such as minimum prices, that could advantage non-Chinese suppliers, according to a draft of an “action plan” seen by Bloomberg. The EU and US would also cooperate on standards, investments and joint projects, as well as coordinate on any supply disruptions by countries like China. The two sides are additionally seeking other “like-minded partners” to join a multicountry accord to help create these new critical mineral supply chains, which feed into
For weeks now, the global tech industry has been waiting for a major artificial intelligence (AI) launch from DeepSeek (深度求索), seen as a benchmark for China’s progress in the fast-moving field. More than a year has passed since the start-up put Chinese AI on the map in early last year with a low-cost chatbot that performed at a similar level to US rivals. However, despite reports and rumors about its imminent release, DeepSeek’s next-generation “V4” model is nowhere in sight. Speculation is also swirling over the geopolitical implications of which computer chips were chosen to train and power the new
RSS